Calypte Biomedical To Hold Investor Call on Tuesday, September 18th To Discuss Significant Corporate Development

Business Wire, Sept 13, 2007

LAKE OSWEGO, Ore. -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer and marketer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that it will hold a conference call for the investment community and other interested parties on Tuesday, September 18, 2007 to discuss a significant corporate development. The Company will issue a press release disclosing the development prior to the opening of the stock market.

The conference call will take place at 10:30 a.m. eastern time. Interested participants should call 866-770-7125 within the United States or 617-213-8066 internationally. Please use passcode 82497678. A playback of the conference will be available two hours after the completion of the call. To listen to the playback, please call 888-286-8010 within the United States or 617-801-6888 internationally. Please use passcode 22450545. The call will also be webcast and will be available on the Company's web site at www.calypte.com in the Investor Relations section under Webcasts and Presentations.

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware[R] HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.